SYRE - Company ID 0001636282
The table below shows Spyre Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$169.25M | -$157.41M | -$99.91M | -$80.14M | -$53.72M | -$75.78M |
| Capital expenditure | - | $0.00 | $0.00 | $38.00K | $573.00K | $4.28M |
| Investing cash flow | -$143.47M | -$353.29M | -$108.39M | $57.01M | -$22.62M | -$7.60M |
| Dividends paid | - | - | - | - |
Spyre Therapeutics, Inc. reported operating cash flow of -$169.25M for fiscal year 2025. That is down 7.5% from -$157.41M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$18.84M (FY 2016) to -$169.25M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $309.02M | $410.91M | $361.08M | $42.68M | $1.39M | $154.51M |